These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38888850)

  • 1. The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism.
    Remmerie M; Dok R; Wang Z; Omella JD; Alen S; Cokelaere C; Lenaerts L; Dreesen E; Nuyts S; Derua R; Janssens V
    Cell Oncol (Dordr); 2024 Oct; 47(5):1811-1829. PubMed ID: 38888850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
    O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
    Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
    Haesen D; Abbasi Asbagh L; Derua R; Hubert A; Schrauwen S; Hoorne Y; Amant F; Waelkens E; Sablina A; Janssens V
    Cancer Res; 2016 Oct; 76(19):5719-5731. PubMed ID: 27485451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
    Shih IeM; Wang TL
    J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
    O'Connor CM; Leonard D; Wiredja D; Avelar RA; Wang Z; Schlatzer D; Bryson B; Tokala E; Taylor SE; Upadhyay A; Sangodkar J; Gingras AC; Westermarck J; Xu W; DiFeo A; Brautigan DL; Haider S; Jackson M; Narla G
    Oncogene; 2020 Jan; 39(3):703-717. PubMed ID: 31541192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPP2R1A mutations are common in the serous type of endometrial cancer.
    Nagendra DC; Burke J; Maxwell GL; Risinger JI
    Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
    Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
    J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
    Haines K; Huang GS
    Cancer Res; 2019 Aug; 79(16):4009-4010. PubMed ID: 31416848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
    Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
    Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
    Black JD; English DP; Roque DM; Santin AD
    Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
    Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
    Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
    Taylor SE; O'Connor CM; Wang Z; Shen G; Song H; Leonard D; Sangodkar J; LaVasseur C; Avril S; Waggoner S; Zanotti K; Armstrong AJ; Nagel C; Resnick K; Singh S; Jackson MW; Xu W; Haider S; DiFeo A; Narla G
    Cancer Res; 2019 Aug; 79(16):4242-4257. PubMed ID: 31142515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
    Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
    Zeng X; Baba T; Hamanishi J; Matsumura N; Kharma B; Mise Y; Abiko K; Yamaguchi K; Horikawa N; Hunstman DG; Mulati K; Kitamura S; Taki M; Murakami R; Hosoe Y; Mandai M
    Int J Cancer; 2019 Sep; 145(6):1635-1647. PubMed ID: 31228268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
    Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
    Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines.
    Guo Y; Xu X; Qi W; Xie C; Wang G; Zhang A; Ge Y
    Mol Med Rep; 2012 Mar; 5(3):734-8. PubMed ID: 22200913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.
    Nagai S; Takenaka K; Nachagari D; Rose C; Domoney K; Sun D; Sparreboom A; Schuetz JD
    Cancer Res; 2011 Mar; 71(5):1781-91. PubMed ID: 21245102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
    Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
    Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
    Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.